Lassogen

Lassogen is a biotechnology company pioneering the development of lasso peptides as a new class of therapeutic agents. Lasso peptides are ribosomally synthesized and post-translationally modified peptides (RiPPs) characterized by a unique knot structure that provides exceptional stability against heat and proteolytic degradation. The company's proprietary platform enables the high-throughput discovery and optimization of these peptides to target traditionally undruggable receptors, such as G protein-coupled receptors (GPCRs) and ion channels. Lassogen's lead programs focus on oncology and chronic pain, leveraging the precision of biologics with the stability of small molecules. By engineering these highly constrained structures, the company aims to create potent and selective treatments for complex diseases.